JavaScript seem to be disabled in your browser.
You must have JavaScript enabled in your browser to utilize the functionality of this website.
Cendakimab (RPC-4046) is a humanized monoclonal antibody that targets IL-13 originally made by Celgene, acquired by Bristol-Myers Squibb that is being developed for the treatment of eosinophilic gastrointestinal disorders.